Information Provided By: 
Fly News Breaks for July 10, 2018
XLRN
Jul 10, 2018 | 05:51 EDT
UBS analyst Carter Gould raised his price target for Acceleron Pharma to $62 citing the positive results from the Phase 3 Believe study of luspatercept in beta-thalassemia. While not a surprise after the positive Medalist data two weeks ago, a "clear clinical win" was important given a lack of quantitative details in either press release, Gould tells investors in a research note. He keeps a Buy rating on Acceleron.
News For XLRN From the Last 2 Days
There are no results for your query XLRN
